AI Science Tracker

Machine learning screening identifies GW3965 activity against invasive group A Streptococcus

West Virginia University · 18 Feb 2026 · biology

Discovery

Machine learning screening identifies GW3965 activity against invasive group A Streptococcus

A neural network trained on measured growth responses from 2,560 compounds screened 6,111 FDA-evaluated compounds for activity against multidrug-resistant emm92 group A Streptococcus. Of nine selected compounds tested, GW3965 reduced bacterial survival by 99% at an MIC of 6.25 μM. The authors also report improved wound closure in an infected human skin-equivalent model and reduced lesion area and bacterial burden in mice. This is preclinical evidence and does not establish efficacy or safety in people. The peer-reviewed journal article followed on 2026-05-30 and reports the same core GW3965 result.

Technology: Deep neural network trained on compound SMILES and measured bacterial growth responses; model screened an FDA-evaluated compound library

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: The model was trained on 2,560 compounds and screened 6,111. Nine selected compounds were validated; GW3965 had MIC 6.25 μM and reduced viable emm92 iGAS by 99%. In a human skin-equivalent model infected tissues treated with GW3965 showed wound closure; in a mouse SSTI model 30 mg/kg reduced lesion size and day-6 wound bacterial burden by about 2 logs on average.
  • Still unknown: Results come from in-vitro assays and animal/tissue models; the preprint reports no synergy with ampicillin. Human clinical efficacy, dosing, safety and mechanism against GAS remain unestablished.
  • AI role: A neural network learned structure–growth-inhibition patterns from measured compound screening data, prioritized GW3965 for follow-up, and the selected candidate was experimentally tested in bacterial, human skin-equivalent, and mouse infection models.

Evidence sources: https://assets-eu.researchsquare.com/files/rs-8779898/v1/a183f808-a19a-41be-8b56-ad4009293888.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary Research Square v1 full-text PDF, including posted date, affiliations, Methods and experimental outcomes; primary Nature publisher indexed article text and journal-version abstract/results..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.